(Adds details on immunity)
By Nikolaj Skydsgaard
COPENHAGEN, June 17 (Reuters) - Denmark will offer COVID-19
vaccines for children aged 12-15 after the adult population has
been inoculated to boost its overall immunity against the virus
ahead of the winter, health authorities said on Thursday.
Initially, Denmark will only offer Pfizer-BioNTech's
COVID-19 vaccine for 12-15 year-olds, as it
is the only vaccine approved by the EU's drug regulator for use
in adolescents, the Danish Health Authority said in a statement.
The EU regulator expects to announce a decision on the use
of Moderna's shot in adolescents sometime next month.
"An expansion of the target group to the 12-15-year-olds is
necessary to ensure even greater immunity in the population, and
thus ensure control of the epidemic in Denmark," the head of the
Danish Health Authority, Soren Brostrom, said.
Vaccination of adolescents would begin after the last adults
have been fully vaccinated in mid-September, Brostrom told a
press briefing.
"We need the immunity of the population, especially before a
winter season," he said.
In an optimal scenario, Brostrom estimated around 75% of
Denmark's population will be immune against the virus after all
adults have been inoculated. Vaccinating the adolescents would
add another 4% to that number, he said.
Danish health authorities would continually review new data
on the vaccine's safety, Brostrom said, and would keep a special
eye on data from the United States, where he said over 3 million
adolescents had already received a jab with the vaccine.
Denmark made waves when it announced in April and May it
would cease to administer vaccines developed by AstraZeneca
and Johnson & Johnson to adults over a potential
link to a rare but serious form of blood clot.
The Nordic country's government has since asked health
authorities to reconsider the exclusion of those vaccines since
new data on their effects and side-effects has been reported.
Almost half of Denmark's population have received a first
vaccine shot while more than a quarter are completely
inoculated.
(Reporting by Nikolaj Skydsgaard; additional reporting by Tim
Barsoe;
Editing by Alison Williams, Robert Birsel and Steve Orlofsky)
Astrazeneca (AZN)
